Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Potential risk factors on vaccine virus shedding and antibody seroresponse to human rotavirus vaccine in Mexican infants: an expanded access program

Trial Profile

Potential risk factors on vaccine virus shedding and antibody seroresponse to human rotavirus vaccine in Mexican infants: an expanded access program

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs RIX 4414 (Primary)
  • Indications Rotavirus infections
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 27 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top